Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SD-101 + BMS-986178 + Radiation in Low-Grade B-Cell Lymphoma
NCT03410901Phase 1Completed
- Start
- Apr 2018
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986178 in B-cell non-Hodgkin lymphoma. Primary endpoints: Number of participants experiencing Dose-limiting Toxicities (DLT) at 8 weeks and Recommended Phase 2 Dose (RP2D) of BMS-986178. Started Apr 2018; status: completed.
02
Drugs
BMS-986178
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03410901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03410901.